Biotech Short Interest NOV 2007 II (AMGN, BIIB, CELG, GENZ, GILD, IMCL, MEDX)

Health and Healthcare

Published: December 11, 2007 5:30 pm

We’ve had a lot of biotech stocks see their shares get the wrath of news over recent days. Now that the November-end NASDAQ Short Interest has been released, we wanted to see how the gains and losses were in short selling activity. Here is the key short selling data on NASDAQ as of November 27, 2007 and Settlement Date of November 30, 2007:

STOCK (Ticker)       Shares Short Change
Amgen (AMGN)       29,112,550    +10.89%
Biogen Idec (BIIB)    6,648,180       (9.58%)
Celgene (CELG)    25,751,400    +12.19%
Genzyme (GENZ)    6,536,150       +12.36%
Gilead (GILD)          25,557,168       (1.59%)
Imclone (IMCL)       4,252,342       (13.49%)
Medarex (MEDX)       30,181,760    (7.72%)

As a reminder, Biogen Idec was the one that Wall Street feels is close to being acquired because of its review being announced.

Jon C. Ogg
December 11, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Get Ready To Retire ^(Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future